Literature DB >> 1931608

Histamine, leukotriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model.

T W Hennigan1, R H Begent, T G Allen-Mersh.   

Abstract

Systemically administered radiolabelled anti-tumour antibody is ineffective in treating the majority of patients with liver metastasis from colorectal carcinoma. We have assessed whether agents which increase capillary permeability can increase tumour uptake of antibody isotope conjugate. We developed a xenograft model of colorectal carcinoma using an antibody directed against carcinoembryonic antigen (CEA). Tumours were grown subcutaneously in the hind limbs of athymic rats to derive their circulation from the femoral artery. Cannulae were placed in the common iliac artery and iliolumbar vein. Antibody was delivered systemically, regionally and regionally with histamine, leukotriene C4 and interleukin-2. Regionally administered anti-CEA antibody resulted in a significantly greater (P = 0.004) tumour to normal tissue ratio (1.66, s.d. = 0.68) compared to systematically administered antibody (1.25, s.d. = 0.73). The addition of vasoactive drugs produced an approximately 3-fold increase with an increase to a mean tumour:liver ratio of 3.24 (s.d. = 1.39) for histamine (P less than 0.001 compared to systemic delivery), 3.21 (s.d. = 1.13, P less than 0.001) for leukotriene C4 and 3.80 (s.d. = 1.53, P less than 0.001) for interleukin-2. The addition of histamine significantly (P = 0.004) increased the mean tumour to liver ratio (1.73, s.d. = 0.44) of non-specific antibody uptake compared with either systemic (1.12, s.d. = 0.24) or regional delivery (1.25, s.d. = 0.54) of non-specific antibody alone. Increasing tumour capillary permeability can produce a significant clinically useful increase in tumour uptake of antibody-isotope conjugate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1931608      PMCID: PMC1977450          DOI: 10.1038/bjc.1991.416

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Interrelationship between mean arterial blood pressure, blood flow, and vascular resistance in solid tumor tissue of DS-carcinosarcoma.

Authors:  P Vaupel
Journal:  Experientia       Date:  1975-05-15

2.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

3.  Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts.

Authors:  H Sands; P L Jones; S A Shah; D Palme; R L Vessella; B M Gallagher
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

4.  Quantitative techniques for study of the anatomy and function of small blood vessels in tumors.

Authors:  I F Tannock; G G Steel
Journal:  J Natl Cancer Inst       Date:  1969-05       Impact factor: 13.506

Review 5.  Radioimmunotherapy of cancer: clinical studies and limiting factors.

Authors:  P W Dykes; A R Bradwell; C E Chapman; A T Vaughan
Journal:  Cancer Treat Rev       Date:  1987-06       Impact factor: 12.111

6.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

7.  Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rat.

Authors:  K F Badr; C Baylis; J M Pfeffer; M A Pfeffer; R J Soberman; R A Lewis; K F Austen; E J Corey; B M Brenner
Journal:  Circ Res       Date:  1984-05       Impact factor: 17.367

8.  Site-related differences in the localization of the monoclonal antibody OX7 in SL2 and SL1 lymphomas.

Authors:  H Sands; P L Jones; W P Neacy; S A Shah; B M Gallagher
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Vascular volume and permeability of human and murine tumors grown in athymic mice.

Authors:  H Sands; S A Shah; B M Gallagher
Journal:  Cancer Lett       Date:  1985-05       Impact factor: 8.679

10.  Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.

Authors:  R H Begent; J A Ledermann; A J Green; K D Bagshawe; S J Riggs; F Searle; P A Keep; T Adam; R G Dale; M G Glaser
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more
  5 in total

Review 1.  Colorectal liver metastases.

Authors:  D Burke; T G Allen-Mersh
Journal:  Postgrad Med J       Date:  1996-08       Impact factor: 2.401

2.  Monoclonal antibodies for the treatment of metastases. Evaluation of strategies using a syngeneic rat model.

Authors:  S A Eccles; G Box; W Court; M K Collins; C J Dean
Journal:  Cell Biophys       Date:  1993 Jan-Jun

3.  A recombinant single-chain antibody interleukin-2 fusion protein.

Authors:  P Savage; A So; R A Spooner; A A Epenetos
Journal:  Cell Biophys       Date:  1993 Jan-Jun

Review 4.  Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.

Authors:  Mikhail O Durymanov; Andrey A Rosenkranz; Alexander S Sobolev
Journal:  Theranostics       Date:  2015-06-08       Impact factor: 11.556

5.  A recombinant single chain antibody interleukin-2 fusion protein.

Authors:  P Savage; A So; R A Spooner; A A Epenetos
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.